Skip main navigation (Press Enter).

FDA Will Reject Petitions Solely Meant to Delay Generic Drugs

Share:

September 25, 2019

The federal drug agency is tightening its reins on industry petitions companies or individuals can submit to influence health policy and says it will outright reject faulty requests intended to delay drug competition.

Related Stories

Get Involved! Volunteer for the New Regulatory Response Subcommittee

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Raw Material Variability and Classification – Thinking beyond the Regulatory Submission

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments September 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments August 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments June 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

«
1
2
3
4
5
...
»

Contact Us:

Kristen Kalmann, Content Manager
2107 Wilson Blvd. Ste. 200
Arlington, VA 22201

Advertising

View the Media Kit

AAPS Customer Service

1-703-243-2800

Copyright © 2024 AAPS Newsmagazine. All rights reserved.

Powered by Higher Logic

Global message icon